BPS Winter Meeting
Joanna Oladipo will be presenting her latest findings on the Poly I:C model for ASD at the British Pharmacological Society winter meeting in Westminster, London on Tuesday 13th December. Do come along and see her poster being presented at 4–6pm.
Jo attended the annual meeting of the Society for Neuroscience on 12–16th November in San Diego, California. She presented a poster of our latest work on development of a neuroimmune animal model for schizophrenia.
Jo attended the 29th annual congress of the European College of Neuropsychopharmacology on 17–20th September in Vienna. She gave a presentation on Tues 20th entitled: “Do tests of affect and anhedonia in animals reflect negative symptoms or depression, and does it matter?” in symposium “Translational models must reflect evolving concepts of psychosis: from psychopathology to pathobiology.”
We presented our latest findings at the 42nd annual meeting of the British Association for Psychopharmacology in Brighton 17–20th July.
Jo became President at this meeting. She presented a talk entitled “Sex and Power: directives about using females in experimental studies” in the preclinical workshop on Sunday 17th, “Reproducibility and Reliability of preclinical research: All in the design?” and co-chaired the symposium “New paradigms and treatment approaches in schizophrenia” on Monday 18th.
At BAP, the b-neuro team presented 5 posters and 1 talk on various topics including: effects of methylphenidate on cortical EEG in anaesthetised rats; effects of exercise in rats to restore cognitive deficits in our sub-chronic PCP model for schizophrenia; development of a neuroimmune animal model; and effects of cannabidiol on cognitive and social behaviour in an animal model for schizophrenia.
We presented a poster and symposium talk showing efficacy of a novel KV3.1 channel modulator, AUT00206 in the sub-chronic PCP model in collaboration with Autifony.
Autifony has successfully completed a Phase I clinical trial with AUT00206. This will be followed by two important Phase 1b trials in collaboration with Bill Deakin at the University of Manchester and Oliver Howes at Kings College London.
Click here to access the press release.